Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · see citing works

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · see citing works

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes

and the WHO Multinational Study Group, Morrish, N. J., Wang, S.-L., Stevens, L. K., Fuller, J. H., & Keen, H. (2001) · Diabetologia · doi:10.1007/pl00002934 · Cited by 1,288 · see citing works

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · see citing works

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works

The Glucagon-Like Peptides

Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,056 · see citing works

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 705 · see citing works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · see citing works

Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure

Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614 · see citing works

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 607 · see citing works

Glucagon-like peptide-1: a potent regulator of food intake in humans

Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 571 · see citing works

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Kolterman, O., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D. S., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 549 · see citing works

Cardiovascular Biology of the Incretin System

Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 527 · see citing works

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats

Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · see citing works

Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men

Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · see citing works

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · see citing works

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works

Glucagon-Like Peptide-1 and Exendin-4 Stimulate β-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age

Tourrel‐Cuzin, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 361 · see citing works

Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes

Fukushima, M., Suzuki, H., & Seino, Y. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.024 · Cited by 313 · see citing works

Glucagon-Like Peptide-1 Inhibits Apoptosis of Insulin-Secreting Cells via a Cyclic 5′-Adenosine Monophosphate-Dependent Protein Kinase A- and a Phosphatidylinositol 3-Kinase-Dependent Pathway

Hui, H., Nourparvar, A., Zhao, X., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2002-220897 · Cited by 307 · see citing works

Effect of linagliptin monotherapy on glycaemic control and markers of β ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Prato, S. D., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. J., & Dugi, K. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 297 · see citing works

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296 · see citing works

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 293 · see citing works

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin

Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · see citing works

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255 · see citing works

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin

Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253 · see citing works

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

Riddle, M. C., Forst, T. M., Aronson, R., Sauque‐Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 251 · see citing works

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226 · see citing works

The Glucagon-Like Peptides

Kieffer, T. J. (1999) · Endocrine Reviews · doi:10.1210/er.20.6.876 · Cited by 219 · see citing works

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218 · see citing works

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus

Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213 · see citing works

Guideline for management of postmeal glucose

Ceriello, A., Colagiuri, S., Gerich, J. E., & Tuomilehto, J. O. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.01.012 · Cited by 208 · see citing works

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

Kapitza, C., Forst, T. M., Coester, H. V., Poitiers, F., Ruus, P., & Hincelin-Méry, A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 192 · see citing works

Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Courrèges, J. P., Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02484.x · Cited by 191 · see citing works

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

Okerson, T. E., Yan, P., Stonehouse, A. H., & Brodows, R. G. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.245 · Cited by 186 · see citing works

Incretin-Based Therapies

Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A. J., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 176 · see citing works

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173 · see citing works

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose‐Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172 · see citing works

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)

Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172 · see citing works

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat

Golpon, H. A., Püchner, A., Welte, T., von Wichert, P., & Feddersen, C. O. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00300-7 · Cited by 158 · see citing works

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

Lorenz, M., Pfeiffer, C., Steinstraesser, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 147 · see citing works

GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery

Richter, G., Feddersen, O. C., Wagner, U., Barth, P. J., Göke, R., & Göke, B. (1993) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1993.265.4.l374 · Cited by 146 · see citing works

Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144 · see citing works

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal ‐P)

Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen-Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 140 · see citing works

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

Tomás, E., & Habener, J. F. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.11.007 · Cited by 135 · see citing works

Proinsulin Is an Independent Predictor of Coronary Heart Disease

Zethelius, B., Byberg, L., Hales, C. N., Lithell, H., & Berne, C. (2002) · Circulation · doi:10.1161/01.cir.0000015855.04844.e7 · Cited by 121 · see citing works

Epidemiology and Economic Impact of Obesity and Type 2 Diabetes

Shamseddeen, H. N., Getty, J. L. Z., Hamdallah, I. N., & Ali, M. R. (2011) · Surgical Clinics of North America · doi:10.1016/j.suc.2011.08.001 · Cited by 118 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 112 · see citing works

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · see citing works

Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp

Zethelius, B., Lithell, H., Hales, C. N., & Berne, C. (2005) · Diabetologia · doi:10.1007/s00125-005-1711-9 · Cited by 111 · see citing works

Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice

Thorkildsen, C., Neve, S., Larsen, B. D., Meier, E., & Petersen, J. S. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051987 · Cited by 99 · see citing works

Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

Yabe, D., Kuroe, A., Lee, S., Watanabe, K., Hyo, T., Hishizawa, M., Kurose, T., Deacon, C. F., Holst, J. J., Hirano, T., et al. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00010.x · Cited by 90 · see citing works

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

Barnett, A. H. (2011) · Core evidence · doi:10.2147/ce.s15525 · Cited by 80 · see citing works

Relationships Among Age, Proinsulin Conversion, and β-Cell Function in Nondiabetic Humans

Fritsche, A., Madaus, A., Stefan, N., Tschritter, O., Maerker, E., Teigeler, A., Häring, H. U., & Stümvoll, M. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s234 · Cited by 80 · see citing works

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

Forst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75 · see citing works

Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study

Forst, T. M., Pfützner, A., Lübben, G., Weber, M. M., Marx, N., Karagiannis, E., Koehler, C., Baurecht, W., Hohberg, C., & Markolf Hanefeld, E. (2007) · Metabolism · doi:10.1016/j.metabol.2006.11.007 · Cited by 67 · see citing works

Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology

Drucker, D. J., & Rosen, C. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2297-z · Cited by 66 · see citing works

Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database

Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M., Pi-Sunyer, F. X., Mills, D., & Dejager, S. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00835.x · Cited by 65 · see citing works

Proinsulin Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality

Alssema, M., Dekker, J. M., Nijpels, G., Stehouwer, C. D. A., Bouter, L. M., & Heine, R. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.860 · Cited by 59 · see citing works

Exenatide once weekly for the treatment of type 2 diabetes

Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55 · see citing works

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

Raccah, D., Miossec, P., Esposito, V., Niemoeller, E., Cho, M., & Gerich, J. E. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2588 · Cited by 50 · see citing works

Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial

van Dieren, S., Czernichow, S., Chalmers, J. P., Kengne, A. P., de Galan, B. E., Poulter, N. R., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., et al. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01556.x · Cited by 48 · see citing works

Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin Analogues

Tews, D., Werner, U., & Eckel, J. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1042426 · Cited by 41 · see citing works

Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men

Wohlin, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00283-1 · Cited by 40 · see citing works

Sex Differences in the Association Between Proinsulin and Intact Insulin With Coronary Heart Disease in Nondiabetic Older Adults

Oh, J. Y., Barrett-Connor, E. L., & Wedick, N. M. (2002) · Circulation · doi:10.1161/hc1102.105565 · Cited by 38 · see citing works

Targeting Plasma Glucose: Preprandial Versus Postprandial

Schrot, R. J. (2004) · Clinical Diabetes · doi:10.2337/diaclin.22.4.169 · Cited by 37 · see citing works

Insulin sensitivity measured by the euglycaemic insulin clamp and proinsulin levels as predictors of stroke in elderly men

Wiberg, B., Sundström, J., Zethelius, B., & Lind, L. (2008) · Diabetologia · doi:10.1007/s00125-008-1171-0 · Cited by 36 · see citing works

Possible involvement of GLP‐1(9–36) in the regional haemodynamic effects of GLP‐1(7–36) in conscious rats

Gardiner, S., March, J., Kemp, P. A., Bennett, T. M., & Dj, B. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00867.x · Cited by 28 · see citing works

The role of incretins in cardiovascular control

Mafong, D. D., & Henry, R. R. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0005-x · Cited by 23 · see citing works

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

Forst, T. M., Dworak, M., Berndt-Zipfel, C., Löffler, A., Klamp, I., Mitry, M., & Pfützner, A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12063 · Cited by 23 · see citing works

Economic considerations in treating patients with type 2 diabetes mellitus

White, J. R. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.suppl_9.s14 · Cited by 21 · see citing works

Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective

Cubbon, R. M., Kahn, M., & Kearney, M. T. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01646.x · Cited by 18 · see citing works

Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?

Ferguson, L. D., & Sattar, N. A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12018 · Cited by 17 · see citing works

Keeping ahead of the fast pace of science

Zierath, J. R. (2010) · Diabetologia · doi:10.1007/s00125-010-1952-0 · Cited by 11 · see citing works

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254 · see citing works

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248 · see citing works

Hydrolyzed Infant Formula and Early β-Cell Autoimmunity

Knip, M., Åkerblom, H. K., BECKER, D. J., Dosch, H.-M., Dupre, J., Fraser, W. D., Howard, N. J., Ilonen, J., Krischer, J. P., Kordonouri, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.5610 · Cited by 173 · see citing works

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152 · see citing works

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes

Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102 · see citing works

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Bentley–Lewis, R., Aguilar, D. A., Riddle, M. C., Claggett, B. L., Díaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L., Lawson, F. C., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 96 · see citing works

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12455 · Cited by 89 · see citing works

Potential side effects to GLP-1 agonists: understanding their safety and tolerability

Consoli, A., & Formoso, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63 · see citing works

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

Scheen, A. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.902444 · Cited by 61 · see citing works

Disturbances in Insulin–Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes

Rahhal, M.-N., Gharaibeh, N. E., Rahimi, L., & Ismail‐Beigi, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00286 · Cited by 60 · see citing works

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58 · see citing works

Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0157-y · Cited by 47 · see citing works

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30 · see citing works

Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor dependent/independent pathways

Abdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 26 · see citing works

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges

Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 26 · see citing works

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal‐related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes

Meier, J. J., Menge, B. A., Schenker, N., Erdmann, S., Kahle, M., Schliess, F., Kapitza, C., & Nauck, M. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13935 · Cited by 23 · see citing works

An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus

Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12469 · Cited by 24 · see citing works

The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation

Xiao, M., Lu, D., Tian, J., Yu, Y., Zhang, Q., Zhang, L., & Chang, D. (2020) · RSC Advances · doi:10.1039/c9ra09959j · Cited by 10 · see citing works

Glucagon-like peptide-1 receptor agonists

Gallwitz, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_3 · Cited by 9 · see citing works

Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography–Tandem Mass Spectrometry Analysis in Rats

Oh, H. S., Park, E. J., Lee, T. S., An, Y., Kim, T. H., Shin, S., & Shin, B. S. (2023) · Separations · doi:10.3390/separations10050282 · Cited by 6 · see citing works

Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors

Engeli, S., & Jordan, J. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000449846.91046.ac · Cited by 3 · see citing works

Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide

Quintilhano, D. L., Miksza, D. R., Galia, W. B. D. S., Ramalho, M. O. R. C., Lucena, C. F., Valle, M. M. R., Graciano, M. F. R., de Souza, H. M., & Bertolini, G. L. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-02006-w · Cited by 3 · see citing works

PRISMA—efficacy and safety of lixisenatide for type 2 diabetes mellitus

Wei, Z., Wang, M., Zhang, H., Wang, Z., Wang, G.-N., Wei, F., Zhang, Y., Xu, X., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000013710 · Cited by 3 · see citing works

Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker‐256 tumour‐bearing rats

Quintilhano, D. L., Miksza, D. R., Biazi, G. R., Frasson‐Uemura, I. G., Graciano, M. F. R., Mazzuco, T. L., Carpinelli, Â. R., de Souza, H. M., & Bertolini, G. L. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3588

Lixisenatide, a novel GLP ‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

Bolli, G. B., & Owens, D. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 37 · see citing works

Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data

Raccah, D. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.82 · Cited by 11 · see citing works

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58 · see citing works

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

Barnett, A. H. (2011) · Core evidence · doi:10.2147/ce.s15525 · Cited by 80 · see citing works

Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness

Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36 · see citing works